NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated July 13, 2026

Febuxostat

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

A non-purine selective xanthine oxidase inhibitor used for the chronic management of hyperuricemia in patients with gout. Febuxostat is indicated as a second-line urate-lowering agent when allopurinol is contraindicated, not tolerated, or fails to achieve target uric acid levels. It carries an FDA black box warning regarding increased cardiovascular death risk.

Evidence tier
Strong
Indexed sources
10 2019–2025
Interactions
0
Category
Prescription
Read the sources → Compare profiles
Publication status

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

A non-purine selective xanthine oxidase inhibitor used for the chronic management of hyperuricemia in patients with gout. NutriStack rates the supporting evidence as strong. Common adult dosing is 40 mg once daily initially; may increase to 80 mg daily if uric acid not <6 mg/dL after 2 weeks (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.

What it's good for
  • Potent reduction of serum uric acid
  • Alternative for patients who cannot tolerate allopurinol1,2
  • No dose adjustment needed for mild-to-moderate renal impairment2
  • Prevention of recurrent gout flares3,4
  • Reduction of tophaceous deposits
What to watch for
  • Liver function abnormalities
  • Nausea
  • Arthralgia
  • Concurrent use with azathioprine or mercaptopurine
  • Known hypersensitivity to febuxostat1,2

The bottom line

Evidence rating strong. Most-documented uses: potent reduction of serum uric acid, alternative for patients who cannot tolerate allopurinol, no dose adjustment needed for mild-to-moderate renal impairment. 10 sources indexed (2019–2025), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Selectively inhibits both the oxidized and reduced forms of xanthine oxidase, blocking the conversion of hypoxanthine to xanthine and xanthine to uric acid. Unlike allopurinol, febuxostat is a non-purine inhibitor and does not require activation by xanthine oxidase, resulting in more potent and sustained uric acid lowering.

Class
Xanthine Oxidase Inhibitor (Gout)
Dosing

Dosing & protocol.

Common range
40 mg once daily initially; may increase to 80 mg daily if uric acid not <6 mg/dL after 2 weeks (as prescribed by your physician)
Recommended form
Tablet

Can be taken with or without food; no significant food-drug interaction2

Safety

Full safety detail.

Side effects

  • Liver function abnormalities
  • Nausea
  • Arthralgia
  • Rash
  • Gout flare during initiation
  • Dizziness
  • Cardiovascular events (MI, stroke)

Contraindications

  • Concurrent use with azathioprine or mercaptopurine
  • Known hypersensitivity to febuxostat1,2
  • Severe hepatic impairment
  • Patients with established cardiovascular disease (use with caution, consider alternatives)1,2
Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Meta-analyses & systematic reviews

5

Reference material

5
FAQ

Common questions.

Quick answers about Febuxostat, drawn from the data on this page.

What is Febuxostat?

A non-purine selective xanthine oxidase inhibitor used for the chronic management of hyperuricemia in patients with gout. Febuxostat is indicated as a second-line urate-lowering agent when allopurinol is contraindicated, not tolerated, or fails to achieve target uric acid levels. It carries an FDA black box warning regarding increased cardiovascular death risk.

What is Febuxostat used for?

Commonly cited benefits of Febuxostat include: Potent reduction of serum uric acid; Alternative for patients who cannot tolerate allopurinol; No dose adjustment needed for mild-to-moderate renal impairment; Prevention of recurrent gout flares; Reduction of tophaceous deposits. NutriStack rates the overall evidence as strong.

What is a typical dose of Febuxostat?

A typical adult dose of Febuxostat is 40 mg once daily initially; may increase to 80 mg daily if uric acid not <6 mg/dL after 2 weeks (as prescribed by your physician). The commonly recommended form is Tablet. These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Febuxostat?

Reported side effects include liver function abnormalities, nausea, arthralgia, rash, gout flare during initiation, dizziness. This is educational information; check with a healthcare professional before use.

How strong is the evidence for Febuxostat?

NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Febuxostat in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

Download on the App Store → Read the methodology

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.